Stiris Research Inc. Announces the First Site Initiated in Phase II Amyotrophic Lateral Sclerosis Trial

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiated in a Phase II Amyotrophic lateral sclerosis (ALS) study.

“Stiris successfully activated its first site for a Phase-II Multicenter Amyotrophic Lateral Sclerosis (ALS) clinical trial on December 1^st, 2023. We are thrilled that this initiation adds foundational support to our client’s endeavour to introduce a new treatment for a rare disease such as ALS that is known to have limited treatment options.” said Shantal Feltham, President & CEO.

Amyotrophic lateral sclerosis (ALS), is a rare neurological disease that affects motor neurons—those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. Nearly all cases of ALS are considered sporadic. This means the disease seems to occur at random with no clearly associated risk factors and no family history of the disease. Although family members of people with sporadic ALS are at an increased risk for the disease, the overall risk is very low and most will not develop ALS. (https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als#:~:text=Amyotrophic%20lateral%20sclerosis%20(ALS)%2C,chewing%2C%20walking%2C%20and%20talking.)